Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Adaptimmune Therapeutics plc ADAP NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • GB • USD

SharesGrow Score
52/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$2.83
+5735.1%

Adaptimmune Therapeutics plc (ADAP) is a Biotechnology company in the Healthcare sector, currently trading at $0.05. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is ADAP = $3 (+5735.1% upside).

Financials: revenue is $178M, +219.6%/yr average growth. Net income is $71M (loss), growing at +21.4%/yr. Net profit margin is -39.8% (negative). Gross margin is 100% (+1806.6 pp trend).

Balance sheet: total debt is $74M against $12M equity (Debt-to-Equity (D/E) ratio 6.26, leveraged). Current ratio is 2.92 (strong liquidity). Debt-to-assets is 30.2%. Total assets: $246M.

Analyst outlook: 9 / 16 analysts rate ADAP as buy (56%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 33/100 (Fail), Moat 58/100 (Partial), Future 64/100 (Pass), Income 10/100 (Fail).

$2.83
▲ 5735.05% Upside
Average Price Target
Based on 16 Wall Street analysts offering 12-month price targets for Adaptimmune Therapeutics plc, the average price target is $2.83, with a high forecast of $4.00, and a low forecast of $1.00.
Highest Price Target
$4.00
Average Price Target
$2.83
Lowest Price Target
$1.00

ADAP SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 58/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ADAP

✓
VALUE Pass
100/100
ADAP trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $3, implying +6085.6% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
ADAP: +219.6%/yr revenue is, +21.4%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet ADAP: Debt-to-Equity (D/E) ratio 6.26 (leveraged), Current ratio is 2.92 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
58/100
ADAP: Gross margin is 100% (+1806.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 58/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 9 / 16 analysts rate ADAP as buy (56%). Analyst consensus target is $3 (+6085.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ADAP: Net profit margin is -39.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.0202-0.86
Volume1.68M
Avg Volume (30D)110.64M
Market Cap$75.16M
Beta (1Y)2.49
Share Statistics
EPS (TTM)-0.28
Shares Outstanding$252.3M
IPO Date2015-05-06
Employees506
CEOAdrian G. Rawcliffe
Financial Highlights & Ratios
Revenue (TTM)$178.03M
Gross Profit$177.96M
EBITDA$-52.67M
Net Income$-70.81M
Operating Income$-68.76M
Total Cash$151.61M
Total Debt$74.21M
Net Debt$-16.93M
Total Assets$245.96M
Price / Earnings (P/E)-0.2
Price / Sales (P/S)0.42
Analyst Forecast
1Y Price Target$3.00
Target High$4.00
Target Low$1.00
Upside+6,085.6%
Rating ConsensusBuy
Analysts Covering16
Buy 56% Hold 25% Sell 19%
Price Target Summary
Company Info
CountryGB
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS00653A1079

Price Chart

Track all markets on TradingView
ADAP
Adaptimmune Therapeutics plc ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.02 52WK RANGE 0.86

People Also View

IMGN
IMGN
ImmunoGen, Inc.
$31.24
+0.02%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 AGIO
AGIO
Agios Pharmaceuticals, Inc.
$33.30
+0.45%
 CRVS
CRVS
Corvus Pharmaceuticals, Inc.
$15.25
+0.53%
 HARP
HARP
Harpoon Therapeutics, Inc.
$23.01
+0.09%
 NKTX
NKTX
Nkarta, Inc.
$2.29
-0.22%
 BDTX
BDTX
Black Diamond Therapeutics, Inc.
$2.66
-2.21%
 SGMO
SGMO
Sangamo Therapeutics, Inc.
$0.26
-0.47%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message